Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARVN NASDAQ:AUPH NASDAQ:RAPP NASDAQ:SNDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$8.03-1.1%$8.16$6.05▼$14.51$518.10M1.74720,899 shs385,661 shsAUPHAurinia Pharmaceuticals$15.35+0.7%$15.99$8.80▼$19.25$1.97B1.411.62 million shs792,501 shsRAPPRapport Therapeutics$40.68-1.7%$38.77$13.62▼$44.28$1.95B0.94448,652 shs269,625 shsSNDXSyndax Pharmaceuticals$20.81-1.9%$20.45$9.42▼$25.59$1.84B0.372.01 million shs1.23 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas0.00%+0.25%0.00%-23.08%+2.03%AUPHAurinia Pharmaceuticals0.00%-3.82%-12.54%-3.94%+67.03%RAPPRapport Therapeutics0.00%-4.55%+4.55%+11.27%+162.45%SNDXSyndax Pharmaceuticals0.00%-8.73%+5.05%-2.71%+103.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$8.03-1.1%$8.16$6.05▼$14.51$518.10M1.74720,899 shs385,661 shsAUPHAurinia Pharmaceuticals$15.35+0.7%$15.99$8.80▼$19.25$1.97B1.411.62 million shs792,501 shsRAPPRapport Therapeutics$40.68-1.7%$38.77$13.62▼$44.28$1.95B0.94448,652 shs269,625 shsSNDXSyndax Pharmaceuticals$20.81-1.9%$20.45$9.42▼$25.59$1.84B0.372.01 million shs1.23 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas0.00%+0.25%0.00%-23.08%+2.03%AUPHAurinia Pharmaceuticals0.00%-3.82%-12.54%-3.94%+67.03%RAPPRapport Therapeutics0.00%-4.55%+4.55%+11.27%+162.45%SNDXSyndax Pharmaceuticals0.00%-8.73%+5.05%-2.71%+103.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARVNArvinas 2.46Hold$15.4291.99% UpsideAUPHAurinia Pharmaceuticals 2.29Hold$17.2512.38% UpsideRAPPRapport Therapeutics 2.91Moderate Buy$57.8642.23% UpsideSNDXSyndax Pharmaceuticals 2.92Moderate Buy$42.55104.45% UpsideCurrent Analyst Ratings BreakdownLatest ARVN, AUPH, RAPP, and SNDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026AUPHAurinia Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/17/2026RAPPRapport Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/16/2026RAPPRapport Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$65.007/15/2026SNDXSyndax Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.007/13/2026ARVNArvinas Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/29/2026AUPHAurinia Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/25/2026ARVNArvinas Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/24/2026SNDXSyndax Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/24/2026RAPPRapport Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$52.006/12/2026SNDXSyndax Pharmaceuticals UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/12/2026SNDXSyndax Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.00(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARVNArvinas$262.60M1.97N/AN/A$6.76 per share1.19AUPHAurinia Pharmaceuticals$283.05M6.97$1.01 per share15.15$4.41 per share3.48RAPPRapport TherapeuticsN/AN/AN/AN/A$10.17 per shareN/ASNDXSyndax Pharmaceuticals$172.35M10.70N/AN/A$0.74 per share28.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARVNArvinas-$80.80M-$3.32N/AN/AN/A-247.54%-44.38%-28.38%8/5/2026 (Estimated)AUPHAurinia Pharmaceuticals$287.20M$2.177.0717.06N/A99.97%26.62%19.65%7/30/2026 (Estimated)RAPPRapport Therapeutics-$111.48M-$2.60N/AN/AN/AN/A-24.78%-23.44%8/6/2026 (Estimated)SNDXSyndax Pharmaceuticals-$285.42M-$2.79N/AN/AN/A-111.88%-256.65%-45.25%8/3/2026 (Estimated)Latest ARVN, AUPH, RAPP, and SNDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026RAPPRapport Therapeutics-$0.9713N/AN/AN/A$2.22 millionN/A8/5/2026Q2 2026ARVNArvinas-$0.24N/AN/AN/A$60.71 millionN/A8/3/2026Q2 2026SNDXSyndax Pharmaceuticals-$0.45N/AN/AN/A$79.36 millionN/A7/30/2026Q2 2026AUPHAurinia Pharmaceuticals$0.19N/AN/AN/A$80.45 millionN/A5/11/2026Q1 2026ARVNArvinas-$0.95-$0.90+$0.05-$0.90$16.61 million$15.60 million5/7/2026Q1 2026AUPHAurinia Pharmaceuticals$0.18$0.25+$0.07$0.25$76.98 million$77.71 million5/7/2026Q1 2026RAPPRapport Therapeutics-$0.56-$0.42+$0.14-$0.42$7.50 million$20.00 million4/30/2026Q1 2026SNDXSyndax Pharmaceuticals-$0.59-$0.48+$0.11-$0.48$69.76 million$64.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARVNArvinasN/AN/AN/AN/AN/AAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/ARAPPRapport TherapeuticsN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARVNArvinasN/A5.445.44AUPHAurinia Pharmaceuticals0.085.555.01RAPPRapport TherapeuticsN/A27.0827.08SNDXSyndax Pharmaceuticals8.265.475.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARVNArvinas95.19%AUPHAurinia Pharmaceuticals36.83%RAPPRapport TherapeuticsN/ASNDXSyndax PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipARVNArvinas7.30%AUPHAurinia Pharmaceuticals10.40%RAPPRapport Therapeutics12.48%SNDXSyndax Pharmaceuticals4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARVNArvinas42064.52 million59.81 millionOptionableAUPHAurinia Pharmaceuticals300128.60 million115.23 millionOptionableRAPPRapport TherapeuticsN/A47.83 million41.86 millionN/ASNDXSyndax Pharmaceuticals11088.61 million84.36 millionOptionableARVN, AUPH, RAPP, and SNDX HeadlinesRecent News About These CompaniesSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Recommendation of "Moderate Buy" from BrokeragesJuly 26 at 2:28 AM | americanbankingnews.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Rating of "Moderate Buy" by BrokeragesJuly 26 at 2:28 AM | marketbeat.comGranahan Investment Management LLC Cuts Stock Position in Syndax Pharmaceuticals, Inc. $SNDXJuly 25 at 6:24 AM | marketbeat.comSyndax Pharmaceuticals (SNDX) Is Up 8.20% in One Week: What You Should KnowJuly 17, 2026 | zacks.comSyndax Pharmaceuticals' (SNDX) Buy Rating Reaffirmed at HC WainwrightJuly 16, 2026 | americanbankingnews.comSyndax Pharmaceuticals (NASDAQ:SNDX) Earns "Buy" Rating from HC WainwrightJuly 15, 2026 | marketbeat.comSyndax Pharmaceuticals, Inc. (SNDX) Discusses Pipeline Expansion and Next Phase of Innovation for Lead Therapies TranscriptJuly 15, 2026 | seekingalpha.comA Fresh Look At Syndax PharmaceuticalsJuly 14, 2026 | seekingalpha.comSyndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis PushJuly 14, 2026 | marketbeat.comSyndax Pharmaceuticals, Inc. (SNDX) Discusses Pipeline Expansion and Next Phase of Innovation for Lead Therapies - SlideshowJuly 14, 2026 | seekingalpha.comWall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a BetJuly 14, 2026 | zacks.comSyndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D EventJuly 14, 2026 | globenewswire.comSyndax Pharmaceuticals (NASDAQ:SNDX) CEO Michael Metzger Sells 32,375 Shares of StockJuly 10, 2026 | insidertrades.comSyndax Pharmaceuticals (NASDAQ:SNDX) CEO Sells 32,375 SharesJuly 9, 2026 | marketbeat.comSG Americas Securities LLC Has $900,000 Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDXJuly 6, 2026 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Draws Fresh Market AttentionJuly 2, 2026 | kalkinemedia.comKSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)July 1, 2026 | globenewswire.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by AnalystsJuly 1, 2026 | marketbeat.comIs Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates?June 30, 2026 | insidermonkey.com3 Biotech Takeover Targets Wall Street Is Watching After the Apogee DealJune 23, 2026 | 247wallst.comSyndax Pharmaceuticals (SNDX) Gets a Buy from GuggenheimJune 14, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARVN, AUPH, RAPP, and SNDX Company DescriptionsArvinas NASDAQ:ARVN$8.03 -0.09 (-1.11%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$8.02 0.00 (-0.06%) As of 07/24/2026 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Aurinia Pharmaceuticals NASDAQ:AUPH$15.35 +0.11 (+0.72%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$15.52 +0.17 (+1.07%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Rapport Therapeutics NASDAQ:RAPP$40.68 -0.70 (-1.69%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$40.69 +0.01 (+0.02%) As of 07/24/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.Syndax Pharmaceuticals NASDAQ:SNDX$20.81 -0.40 (-1.89%) As of 07/24/2026 04:00 PM EasternSyndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade? Broadcom May Be the Biggest Winner From Alphabet's Earnings CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
